MICHAEL CAMILLERI, M.D.
Osteopathic Medicine at 1 St, Rochester, MN
License number
Minnesota 32016
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Organization information
See more information about MICHAEL CAMILLERI at bizstanding.comMichael Camilleri MD
Rochester, MN
Industry:
Gastroenterologist, Dermatologist, Internist
Phone:
(507) 284-2511 (Phone)
Addresses:
932 4 St SW, Rochester, MN 55902
200 1 St SW, Rochester, MN 55902
200 1 St SW, Rochester, MN 55902
Medical Doctor:
Michael Camilleri (Medical Doctor)
Michael Camilleri MD
200 1 St SW, Rochester, MN 55905
Industry:
Dermatologist, Internist
Phone:
(507) 284-2141 (Phone)
Michael Joseph Camilleri
Professional information
Professor At Mayo Clinic
Position:
Professor at Mayo Clinic
Location:
Rochester, Minnesota Area
Industry:
Medical Practice
Work:
Mayo Clinic
-
Professor
Professor At Mayo Clinic
Position:
Professor at Mayo Clinic
Location:
Rochester, Minnesota Area
Industry:
Medical Practice
Work:
Mayo Clinic
-
Professor
Michael Joseph Camilleri, Rochester MN
Specialties:
Dermatology, Dermatopathology, Gastroenterology, Hepatology
Work:
Mayo Medical School
200 1St St Sw, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
Education:
Univ Of Malta, Med Sch, Guardamangia, Malta (1989)
Michael J Camilleri, Rochester MN
Specialties:
Gastroenterologist
Address:
Mayo Clinic, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
Charcoal-Radionuclide Agents For Measurement Of Gastrointestinal Transit
US Patent:
5827497, Oct 27, 1998
Filed:
Aug 14, 1996
Appl. No.:
8/698209
Inventors:
Michael Camilleri - Rochester MN
Joseph C. Hung - Rochester MN
Brian P. Mullan - Rochester MN
Joseph C. Hung - Rochester MN
Brian P. Mullan - Rochester MN
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A61K 5104
US Classification:
424 137
Abstract:
A unit dosage form is provided which comprises an effective amount of a radioisotope adsorbed onto activated charcoal, and which is preferably enterically coated. The unit dosage form is useful for the measurement of intestinal transit.
Obesity Treatment And Device
US Patent:
8372158, Feb 12, 2013
Filed:
Sep 22, 2010
Appl. No.:
12/887714
Inventors:
Michael J. Levy - Rochester MN, US
Michael L. Camilleri - Rochester MN, US
Joseph A. Murray - Rochester MN, US
William J. Sandborn - Rochester MN, US
Michael L. Camilleri - Rochester MN, US
Joseph A. Murray - Rochester MN, US
William J. Sandborn - Rochester MN, US
Assignee:
EnteroMedics, Inc. - St. Paul MN
International Classification:
A61M 5/00, A61F 2/04
US Classification:
623 2368, 604 8, 604 9, 623 2364, 623 2365, 623 2367
Abstract:
A method and apparatus are disclosed for treating obesity includes an artificial fistula created between gastrointestinal organs such as between the stomach and the colon. The method includes selecting an implant comprising a passageway having an internal lumen with an inlet end and an outlet end. The passageway is positioned passing through a first wall of first gastrointestinal organ (for example, passing through the wall of the stomach) and a second wall of a second gastrointestinal organ (for example, passing through the wall of the large intestine) with the inlet end disposed within an interior of the first gastrointestinal organ and with the outlet disposed within an interior of the second gastrointestinal organ.
Predicting Patient Responsiveness To Serotonergic Therapy
US Patent:
2003014, Jul 31, 2003
Filed:
Jan 28, 2002
Appl. No.:
10/058630
Inventors:
Michael Camilleri - Rochester MN, US
Raul Urrutia - Rochester MN, US
Raul Urrutia - Rochester MN, US
International Classification:
C12Q001/68, C12P019/34
US Classification:
435/006000, 435/091200
Abstract:
Methods to predict a patient's responsiveness to 5-HTreceptor antagonists are disclosed. The methods allow a clinician to predict a patient's responsiveness to 5-HTreceptor antagonists by determining the correlation that exists between a genotype in the promoter region of the gene encoding a serotonin transporter protein and patient response to 5-HTreceptor antagonist therapy. In addition, methods to treat patients suffering from diarrhea-predominant irritable bowel syndrome and methods to identify a patient population for inclusion in a 5-HTreceptor antagonist clinical trial are disclosed.
Gastric Reshaping Devices And Methods
US Patent:
2006002, Jan 26, 2006
Filed:
Jul 19, 2005
Appl. No.:
11/185213
Inventors:
Christopher Gostout - Rochester MN, US
Elizabeth Rajan - Rochester MN, US
Joseph Murray - Rochester MN, US
Michael Camilleri - Rochester MN, US
Elizabeth Rajan - Rochester MN, US
Joseph Murray - Rochester MN, US
Michael Camilleri - Rochester MN, US
International Classification:
A61B 17/08
US Classification:
606153000
Abstract:
Gastric volume of a patient is reduced by deploying an endoscope into a stomach through the esophagus. A plurality of anterior anchors are affixed to the anterior wall of the stomach. The anterior anchors are distributed along an anterior line of the stomach wall beginning near the cardia region and extending toward the stomach exit. A plurality of posterior anchors are affixed to the posterior wall of the stomach. The posterior anchors are distributed along a posterior line of the stomach wall beginning near the cardia region and toward the stomach exit. The anchor line and the stomach wall are drawn towards the posterior line of the stomach wall to reduce gastric volume.
Systems And Methods For Curbing Appetite
US Patent:
2006002, Jan 26, 2006
Filed:
Aug 23, 2004
Appl. No.:
10/924249
Inventors:
Michael Camilleri - Rochester MN, US
Joseph Murray - Rochester MN, US
Joseph Murray - Rochester MN, US
International Classification:
A61N 1/20
US Classification:
607040000
Abstract:
Methods and systems to replace and/or enhance a normal satiety signal with, e.g., an appetite control signal to curb appetite are disclosed. The appetite control signal may, e.g., enhance or accelerate the normal satiety signal and/or provide a nauseous signal in order to reduce a patient's appetite. The effector that provides the appetite control signal may function by delivering signals that are, e.g., chemical, pharmacological, electrical, biological, thermal, etc. (and combinations thereof). The system may function by sensing early physiological responses to eating using one or physiological sensors. When the physiological responses reach a predetermined level, the effector component may be activated to provide one or more selected appetite control stimuli (e.g., noxious stimuli, enhanced or accelerated satiety stimuli, etc.).
Compositions And Methods For Treating And Diagnosing Irritable Bowel Syndrome
US Patent:
2010022, Sep 2, 2010
Filed:
Oct 11, 2007
Appl. No.:
12/445144
Inventors:
Theodoor Victor Constant Thielemans - Beerse, BE
Jeroen Marcel Maria Roger Aerssens - Nieuwrode, BE
Willem Jan-Paul Edmond Talloen - Antwerpen, BE
Leen Albert Leonarda Thielemans - Vosselaar, BE
Michael L. Camilleri - Rochester MN, US
Jeroen Marcel Maria Roger Aerssens - Nieuwrode, BE
Willem Jan-Paul Edmond Talloen - Antwerpen, BE
Leen Albert Leonarda Thielemans - Vosselaar, BE
Michael L. Camilleri - Rochester MN, US
Assignee:
JANSSEN PHARMACEUTICA N.V. - Beerse
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
C40B 30/04, C12Q 1/68, G01N 33/53
US Classification:
506 9, 435 6, 435 71
Abstract:
The present invention relates generally to therapy and diagnosis of disorders associated with chronic visceral hypersensitivity (CVH), and in particular irritable bowel syndrome (IBS). In particular, this invention relates to the polypeptides as well as to the polynucleotides encoding these polypeptides, wherein said polypeptides are shown to be associated with CVH. These polypeptides and polynucleotides are useful in the diagnosis, treatment and/or prevention of disorders associated with CVH, in particular in the diagnosis, treatment and/or prevention of disorders associated with IBS.